| __timestamp | Insmed Incorporated | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 33534999 | 25434000 |
| Thursday, January 1, 2015 | 1982000 | 23783000 |
| Friday, January 1, 2016 | 2438000 | 29763000 |
| Sunday, January 1, 2017 | 2901000 | 12065000 |
| Monday, January 1, 2018 | 2423000 | 5508000 |
| Tuesday, January 1, 2019 | 24212000 | 75173000 |
| Wednesday, January 1, 2020 | 39872000 | 81497000 |
| Friday, January 1, 2021 | 44152000 | 85731000 |
| Saturday, January 1, 2022 | 55126000 | 63572000 |
| Sunday, January 1, 2023 | 65573000 | 54922000 |
| Monday, January 1, 2024 | 41070000 |
Igniting the spark of knowledge
In the ever-evolving landscape of biotechnology, understanding cost structures is crucial. From 2014 to 2023, Insmed Incorporated and Mesoblast Limited have shown distinct trajectories in their cost of revenue. Insmed's costs surged by over 1,200%, peaking in 2023, reflecting strategic investments in research and development. Meanwhile, Mesoblast's costs fluctuated, reaching a high in 2021 before declining by 36% by 2023. This divergence highlights differing operational strategies and market responses. Notably, Insmed's consistent growth contrasts with Mesoblast's volatility, offering insights into their financial health and market positioning. As we look to 2024, Mesoblast's missing data suggests potential shifts or strategic pivots. Investors and stakeholders should consider these trends when evaluating future prospects in the biotech sector.
Cost of Revenue Comparison: Amgen Inc. vs Insmed Incorporated
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Mesoblast Limited
Cost Insights: Breaking Down Biogen Inc. and Mesoblast Limited's Expenses
Comparing Cost of Revenue Efficiency: United Therapeutics Corporation vs Insmed Incorporated
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Mesoblast Limited
Comparing Cost of Revenue Efficiency: Insmed Incorporated vs Pharming Group N.V.
Cost of Revenue Comparison: Insmed Incorporated vs Veracyte, Inc.
Cost of Revenue Comparison: Insmed Incorporated vs Agios Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Insmed Incorporated and Amphastar Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Insmed Incorporated vs Mesoblast Limited
Analyzing Cost of Revenue: Walgreens Boots Alliance, Inc. and Mesoblast Limited
Cost of Revenue Comparison: ADMA Biologics, Inc. vs Mesoblast Limited